Fig. 2: The genomic landscape and mutational signatures in OAC.

a Bar plots displaying the genomic features of OAC samples within the cohort, with samples sorted by overall survival. The colour bar above the figure represents from top to bottom: stage, allocated treatment, PET response and tumour cellularity. The histograms from top to bottom are: overall patient survival with white bars are patients who are alive and black who are dead, the mutations per megabase, the number of neoantigens, the proportion of mutational signatures from SNV, the number and type of SVs, and the proportion of structural variant signatures. Clinical features per sample are annotated above the bar plots. b Pearson correlation (two-sided) of percent of mutational signature 17 burden (y-axis) with the total number of SNVs (x-axis) in each tumour (n = 89 biologically independent samples). Shading indicates 95% confidence intervals. c–e Kaplan–Meier plots of overall patient survival (log-rank test) with the number of patients (biologically independent samples) in each group shown in the table below each plot. Samples are stratified by the prevalence of c the APOBEC mutational signature (present ≥15% in a sample n = 8 and absent <15% n = 81), d RS3-like structural variant signature with samples stratified into low (lower tertile, n = 30) and high (upper tertile, n = 29) groups and e RS5-like structural variant signature with samples stratified into low (lower tertile, n = 30) and high (upper tertile, n = 29) groups. PET, positron emission tomography; CF, Cisplatin and 5-Fluorouracil; DCF, CF and docetaxel; RT, 45 Gy radiotherapy. Source data are provided as a Source data file.